🇨🇭September 22, 2026·12h agoIndustry

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity

Publisher

Roche Newsroom

Switzerland

This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: Roche Newsroom
Region: Switzerland
Scope: Industry
Published: September 22, 2026

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on roche.com

Leave the platform to read the original full article on the publisher site.

Source: Roche Newsroom

Scope: Industry

Open original article

Related coverage

More related coverage

Merck & Co. (MSD) News/6h ago

U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

Aspen Pharmacare/9h ago

How Aspen’s Priyen Naidu drives a human-centred approach to technology

Ipsen/10h ago

Building on Success: Ipsen Receives Two New Gold Brandon Hall Awards

Ipsen RSS/10h ago